SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Eagle Pharmaceuticals, Inc. EGRX OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Eagle Pharmaceuticals, Inc. (EGRX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.34. It has a SharesGrow Score of 72/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $317M, +23.9%/yr average growth. Net income is $36M, growing at +108.3%/yr. Net profit margin is 11.3% (healthy). Gross margin is 70% (+1.1 pp trend).

Balance sheet: total debt is $68M against $234M equity (Debt-to-Equity (D/E) ratio 0.29, conservative). Current ratio is 1.7 (strong liquidity). Debt-to-assets is 16.7%. Total assets: $406M.

Analyst outlook: 2 / 6 analysts rate EGRX as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 54/100 (Partial), Future 20/100 (Fail), Income 55/100 (Partial).

EGRX SharesGrow Score Overview

72/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 75/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 54/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EGRX

EGRX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

EGRX: +23.9%/yr revenue is, +108.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

EGRX: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet EGRX: Debt-to-Equity (D/E) ratio 0.29 (conservative), Current ratio is 1.7 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

EGRX: Gross margin is 70% (+1.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 54/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 6 analysts rate EGRX as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

EGRX: Net profit margin is 11.3%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.085-3.87

Volume560

Avg Volume (30D)3.79K

Market Cap$4.43M

Beta (1Y)0.31

Share Statistics

EPS (TTM)2.76

Shares Outstanding$12.93M

IPO Date2014-02-12

Employees134

CEOMichael Graves

Financial Highlights & Ratios

Revenue (TTM)$316.61M

Gross Profit$221.67M

EBITDA$106.83M

Net Income$35.64M

Operating Income$80.96M

Total Cash$55.32M

Total Debt$67.79M

Net Debt$12.47M

Total Assets$406.16M

Price / Earnings (P/E)0.1

Price / Sales (P/S)0.01

Analyst Forecast

Rating ConsensusHold

Analysts Covering6

Buy 33% Hold 50% Sell 17%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS2697961082

Price Chart

EGRX

Eagle Pharmaceuticals, Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

0.09 52WK RANGE 3.87

People Also View

Regencell Bioscience Holdings Limited

Prestige Consumer Healthcare Inc.

Phibro Animal Health Corporation

Deciphera Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

Collegium Pharmaceutical, Inc.

Amphastar Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message